BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Minerva Neuroscience (NERV)Minerva NeuroscienceClinical readout

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on

Related news

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

ANVSAnnovis Bio2026-07-01 12:00 EST

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

ANNXAnnexon, Inc.2026-07-14 20:05 EST

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

VYGRVoyager Therapeutics2026-07-13 12:01 EST

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

ACIUAC Immune2026-06-11 11:00 EST

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

View all latest news

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

NERVMinerva Neuroscience2026-05-05 12:00 EST

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-04-02 20:05 EST

Minerva Announces Leadership Transition

Stock data

Close
4.44 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States